{
  "source": "PA-Med-Nec-CGRP-Receptor-Antagonists.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2146-14\nProgram Prior Authorization/Medical Necessity\nMedication Aimovig® (erenumab), Ajovy® (fremanezumab)*, Emgality®\n(galcanezumab)\nP&T Approval Date 6/2018, 10/2018, 11/2018, 2/2019, 6/2019, 7/2019, 7/2020, 7/2021,\n3/2022, 5/2022, 5/2023, 3/2024, 6/2024, 2/2025\nEffective Date 5/1/2025\n1. Background:\nAimovig, Ajovy*and Emgality 120 mg are calcitonin gene-related peptide receptor (CGRP)\nantagonists indicated for the preventive treatment of migraine in adults. The 100 mg strength of\nEmgality is indicated for the treatment of episodic cluster headache in adults.\n2. Coverage Criteriaa:\nA. Migraines\n1. Initial Therapy\na. Aimovig or Emgality (120 mg strength) will be approved based upon all of the\nfollowing criteria:\n1) Diagnosis of migraine consistent with The International Classification of\nHeadache Disorders, 3rd edition\n-AND-\n2) One of the following:\na) 4 to 7 migraine days per month and at least one of the following:\n(1) Less than 15 headache days per month\n-OR-\n(2) Provider attests this is the member’s predominant headache diagnosis\n(i.e., primary driver of headaches is not a different, non-migrainous\ncondition)\n-OR-\nb) Greater than or equal to 8 migraine days per month\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n1\n3) Failure (after a trial of at least two monthsb), contraindication or intolerance to\ntwo of the following prophylactic therapies (document name and date tried)c:\na) One of the following beta-blockers: atenolol, metoprolol, nadolol,\npropranolol, or timolol\nb) Candesartan (Atacand)\nc) Divalproex sodium (Depakote/Depakote ER)\nd) OnabotulinumtoxinA (Botox) [Note: Coverage of onabotulinumtoxinA\n(Botox) may be subject to additional benefit and coverage review\nrequirements]\ne) a serotonin-norepinephrine reuptake inhibitor [i.e., duloxetine (Cymbalta),\nvenlafaxine (Effexor/Effexor XR)]\nf) Topiramate (Topamax)\ng) a tricyclic antidepressant [i.e., amitriptyline (Elavil), nortriptyline ",
    "in-norepinephrine reuptake inhibitor [i.e., duloxetine (Cymbalta),\nvenlafaxine (Effexor/Effexor XR)]\nf) Topiramate (Topamax)\ng) a tricyclic antidepressant [i.e., amitriptyline (Elavil), nortriptyline (Pamelor)]\n-AND-\n4) Medication will not be used in combination with another CGRP antagonist or\ninhibitor used for the preventive treatment of migraines [e.g. Ajovy*, Nurtec®\nODT, Qulipta, Vyepti® (eptinezumab-jjmr)^]\nb. Ajovy* will be approved based upon all of the following criteria:\n1) Diagnosis of migraine consistent with The International Classification of\nHeadache Disorders, 3rd edition\n-AND-\n2) One of the following:\na) 4 to 7 migraine days per month and at least one of the following:\n(1) Less than 15 headache days per month\n-OR-\n(2) Provider attests this is the member’s predominant headache diagnosis\n(i.e., primary driver of headaches is not a different, non-migrainous\ncondition)\n-OR-\nb) Greater than or equal to 8 migraine days per month\n-AND-\n3) Failure (after a trial of at least two monthsb), contraindication or intolerance to\ntwo of the following prophylactic therapies from the list below (document name\nand date tried)c:\n© 2025 UnitedHealthcare Services, Inc.\n2\na) One of the following beta-blockers: atenolol, metoprolol, nadolol,\npropranolol, or timolol\nb) Candesartan (Atacand)\nc) Divalproex sodium (Depakote/Depakote ER)\nd) OnabotulinumtoxinA (Botox) [Note: Coverage of onabotulinumtoxinA\n(Botox) may be subject to additional benefit and coverage review\nrequirements]\ne) a serotonin-norepinephrine reuptake inhibitor [i.e., duloxetine (Cymbalta),\nvenlafaxine (Effexor/Effexor XR)]\nf) Topiramate (Topamax)\ng) a tricyclic antidepressant [i.e., amitriptyline (Elavil), nortriptyline (Pamelor)]\n-AND-\n4) Failure (after a trial of at least three monthsb), contraindication or intolerance to\ntwo of the following (document date tried):\na) Aimovig\nb) Emgality (120 mg strength)\nc) Nurtec ODT\nd) Qulipta\n-AND-\n5) Medication will not be used in combination with another CGRP antagon",
    "tolerance to\ntwo of the following (document date tried):\na) Aimovig\nb) Emgality (120 mg strength)\nc) Nurtec ODT\nd) Qulipta\n-AND-\n5) Medication will not be used in combination with another CGRP antagonist or\ninhibitor used for the preventive treatment of migraines (e.g., Aimovig, Emgality,\nNurtec ODT, Qulipta, Vyepti^)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Aimovig, Ajovy* or Emgality (120 mg strength) will be approved based on all of\nthe following criteria:\n1) Patient has experienced a positive response to therapy, demonstrated by a\nreduction in headache frequency and/or intensity\n-AND-\n2) Medication will not be used in combination with another CGRP antagonist or\ninhibitor used for the preventive treatment of migraines (e.g., Nurtec ODT,\nQulipta, Vyepti^)\nAuthorization will be issued for 12 months.\nB. Episodic Cluster Headache\n1. Initial Therapy\n© 2025 UnitedHealthcare Services, Inc.\n3\na. Emgality (100 mg strength) will be approved based upon all of the following\ncriteria:\n(1) Diagnosis of episodic cluster headache\n-AND-\n(2) Patient has experienced at least 2 cluster periods lasting from 7 days to 365 days,\nseparated by pain-free periods lasting at least three months.\n-AND-\n(3) Medication will not be used in combination with another CGRP antagonist or\ninhibitor used for the preventive treatment of migraines (e.g., Aimovig, Ajovy*,\nNurtec ODT, Qulipta, Vyepti^)\nAuthorization will be issued for12 months.\n2. Reauthorization\na. Emgality (100 mg strength) will be approved based on all of the following criteria:\n(1) Patient has experienced a positive response to therapy, demonstrated by a\nreduction in headache frequency and/or intensity\n-AND-\n(2) Medication will not be used in combination with another CGRP antagonist or\ninhibitor used for the preventive treatment of migraines (e.g., Aimovig, Ajovy*,\nNurtec ODT, Qulipta, Vyepti^)\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the me",
    "tive treatment of migraines (e.g., Aimovig, Ajovy*,\nNurtec ODT, Qulipta, Vyepti^)\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\nb For Connecticut, Kentucky and Mississippi business, only a 30-day trial will be required.\nc For California business a trial of non-CGRP preventive treatments will not be required.\n* Ajovy, is typically excluded from benefit coverage.\n^Vyepti may be subject to additional benefit and coverage review requirements.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim\nlogic. Use of automated approval and re-approval processes varies by program and/or\ntherapeutic class.\n• Notification, Step Therapy and Supply limits may be in place.\n© 2025 UnitedHealthcare Services, Inc.\n4\n4. References:\n1. Aimovig [package insert]. Thousand Oaks, CA: Amgen Inc; August 2024.\n2. Ajovy [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc; October 2022.\n3. Emgality [package insert]. Indianapolis, IN: Eli Lilly and Company; March 2021.\n4. International Headache Society (IHS); Headache Classification Committee. The International\nClassification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38:1-211.\n5. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of\nmigraine: An American Headache Society position statement update. AHS Consensus Statement.\nHeadache. 2024; 64:333-41.\n6. Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: Botulinum\nneurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache:\nReport of the Guideline Development Subcommittee of the American Academy of Neurology.\nNeuro",
    "Botulinum\nneurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache:\nReport of the Guideline Development Subcommittee of the American Academy of Neurology.\nNeurology. 2016 May 10;86(19):1818-26.\nProgram Prior Authorization/Medical Necessity – CGRP antagonists\nChange Control\n6/2018 New program.\n8/2018 Administrative update. Documented CT and KY duration of trial\nregulation\n10/2018 Added Ajovy and Emgality. Modified the trial and failure requirement\nand removed the documentation requirement. Updated references.\n11/2018 Removed the prescriber requirement.\n2/2019 Modified the step therapy requirements for Ajovy.\n6/2019 Removed - Medication will not be used in combination with\nonabotulinumtoxinA (Botox) requirement.\n7/2019 Added the episodic cluster headache indication and included approvable\nstrength for episodic and chronic migraine.\n7/2020 Annual review. Updated initial authorization duration. Added\ndocumentation requirement. Modified concomitant CGRP use to allow\nnon-biologic CGRPs.\n7/2021 Annual review. Updated the criteria for episodic migraines. Combined\nthe criteria for episodic and chronic migraines. Added statement\nregarding concomitant therapy with other preventive CGRPs. Updated\nreferences.\n3/2022 Added candesartan as a preventive option. Updated mandate language.\nAdded Qulipta as CGRP to not be used in combination with. Updated\nthe products typically excluded from coverage. Added note for Vyetpi\nregarding additional benefit and coverage review requirements.\nUpdated references.\n5/2022 Updated the migraine diagnostic criteria. Added Mississippi to state\nmandate language.\n5/2023 Annual review. Updated references.\n© 2025 UnitedHealthcare Services, Inc.\n5\n3/2024 Annual review. Updated initial authorization to 12 months. Added\nepisodic to cluster headaches in section header. Updated mandate\nlanguage. Updated references.\n6/2024 Removed notation that Qulipta is typically excluded from coverage.\nUpdated references.\n2/2025 Added ",
    "isodic to cluster headaches in section header. Updated mandate\nlanguage. Updated references.\n6/2024 Removed notation that Qulipta is typically excluded from coverage.\nUpdated references.\n2/2025 Added footnote for California specific requirement. Updated list of\npotential prophylactic therapies. Added oral CGRP to the list of\nrequired options for Ajovy. Updated references.\n© 2025 UnitedHealthcare Services, Inc.\n6"
  ]
}